vs
Side-by-side financial comparison of Allstate (ALL) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Allstate is the larger business by last-quarter revenue ($922.0M vs $622.0M, roughly 1.5× Royalty Pharma plc). Allstate runs the higher net margin — 266.6% vs 34.4%, a 232.2% gap on every dollar of revenue. On growth, Allstate posted the faster year-over-year revenue change (7.2% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ALL vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $622.0M |
| Net Profit | $2.5B | $214.2M |
| Gross Margin | — | — |
| Operating Margin | -1400.3% | 62.4% |
| Net Margin | 266.6% | 34.4% |
| Revenue YoY | 7.2% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | $9.25 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | — | ||
| Q4 25 | $17.3B | $622.0M | ||
| Q3 25 | $17.3B | $609.3M | ||
| Q2 25 | $16.6B | $578.7M | ||
| Q1 25 | $16.5B | $568.2M | ||
| Q4 24 | $16.5B | $593.6M | ||
| Q3 24 | $16.6B | $564.7M | ||
| Q2 24 | $15.7B | $537.3M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $3.8B | $214.2M | ||
| Q3 25 | $3.7B | $288.2M | ||
| Q2 25 | $2.1B | $30.2M | ||
| Q1 25 | $595.0M | $238.3M | ||
| Q4 24 | $1.9B | $208.2M | ||
| Q3 24 | $1.2B | $544.0M | ||
| Q2 24 | $331.0M | $102.0M |
| Q1 26 | -1400.3% | — | ||
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 50.2% |
| Q1 26 | 266.6% | — | ||
| Q4 25 | 22.1% | 34.4% | ||
| Q3 25 | 21.7% | 47.3% | ||
| Q2 25 | 12.7% | 5.2% | ||
| Q1 25 | 3.6% | 41.9% | ||
| Q4 24 | 11.7% | 35.1% | ||
| Q3 24 | 7.2% | 96.3% | ||
| Q2 24 | 2.1% | 19.0% |
| Q1 26 | $9.25 | — | ||
| Q4 25 | $14.24 | $0.49 | ||
| Q3 25 | $13.95 | $0.67 | ||
| Q2 25 | $7.76 | $0.07 | ||
| Q1 25 | $2.11 | $0.55 | ||
| Q4 24 | $7.07 | $0.46 | ||
| Q3 24 | $4.33 | $1.21 | ||
| Q2 24 | $1.13 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $31.6B | $9.7B |
| Total Assets | $124.0B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $618.7M | ||
| Q3 25 | $8.7B | $938.9M | ||
| Q2 25 | $9.6B | $631.9M | ||
| Q1 25 | $6.5B | $1.1B | ||
| Q4 24 | $4.5B | $929.0M | ||
| Q3 24 | $7.0B | $950.1M | ||
| Q2 24 | $5.3B | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | $9.0B | ||
| Q3 25 | $8.1B | $8.9B | ||
| Q2 25 | $8.1B | $8.0B | ||
| Q1 25 | $8.1B | $7.6B | ||
| Q4 24 | $8.1B | $7.6B | ||
| Q3 24 | $8.1B | $7.6B | ||
| Q2 24 | $8.1B | $7.6B |
| Q1 26 | $31.6B | — | ||
| Q4 25 | $30.6B | $9.7B | ||
| Q3 25 | $27.5B | $9.6B | ||
| Q2 25 | $24.0B | $9.5B | ||
| Q1 25 | $22.1B | $9.8B | ||
| Q4 24 | $21.4B | $10.3B | ||
| Q3 24 | $20.9B | $10.3B | ||
| Q2 24 | $18.6B | $9.8B |
| Q1 26 | $124.0B | — | ||
| Q4 25 | $119.8B | $19.6B | ||
| Q3 25 | $120.4B | $19.3B | ||
| Q2 25 | $115.9B | $18.3B | ||
| Q1 25 | $115.2B | $17.6B | ||
| Q4 24 | $111.6B | $18.2B | ||
| Q3 24 | $113.7B | $18.0B | ||
| Q2 24 | $108.4B | $17.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | 0.92× | ||
| Q3 25 | 0.29× | 0.93× | ||
| Q2 25 | 0.34× | 0.84× | ||
| Q1 25 | 0.37× | 0.78× | ||
| Q4 24 | 0.38× | 0.74× | ||
| Q3 24 | 0.39× | 0.74× | ||
| Q2 24 | 0.43× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $827.1M | ||
| Q3 25 | $3.3B | $702.6M | ||
| Q2 25 | $1.9B | $364.0M | ||
| Q1 25 | $2.0B | $596.1M | ||
| Q4 24 | $1.7B | $742.5M | ||
| Q3 24 | $3.2B | $703.6M | ||
| Q2 24 | $2.4B | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $2.3B | — |
| Q1 26 | — | — | ||
| Q4 25 | 16.7% | — | ||
| Q3 25 | 18.8% | — | ||
| Q2 25 | 11.3% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 10.0% | — | ||
| Q3 24 | 18.9% | — | ||
| Q2 24 | 14.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 0.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | 3.86× | ||
| Q3 25 | 0.88× | 2.44× | ||
| Q2 25 | 0.89× | 12.06× | ||
| Q1 25 | 3.30× | 2.50× | ||
| Q4 24 | 0.88× | 3.57× | ||
| Q3 24 | 2.69× | 1.29× | ||
| Q2 24 | 7.13× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALL
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
